Compare

BioMarin Pharmaceutical Inc vs United Therapeutics Corp vs Amneal Pharmaceuticals, Inc. vs Alnylam Pharmaceuticals, Inc.

Latest annual figures from SEC filings. Each company is shown for its own most recent fiscal year, so period ends can differ. Select a figure to see its full history.

Latest fiscal year	BioMarin Pharmaceutical Inc BMRN	United Therapeutics Corp UTHR	Amneal Pharmaceuticals, Inc. AMRX	Alnylam Pharmaceuticals, Inc. ALNY
Year ended	2025-12-31	2025-12-31	2025-12-31	2025-12-31
Revenue	$3.22B	$3.18B	$3.02B	$3.71B
Revenue growth (YoY)	+12.9%	+10.6%	+8.0%	+65.2%
Gross margin	77.7% (computed)	87.9% (computed)	36.9%	81.8% (computed)
Operating margin	12.7%	46.9%	13.1%	13.5%
Net margin	10.8%	41.9%	2.4%	8.4%
Net income	$348.90M	$1.33B	$72.06M	$313.75M
EPS (Diluted)	$1.80	$27.86	$0.22	$2.33
Operating cash flow	$827.99M	$1.56B	$339.99M	$524.08M
Free cash flow	$724.96M	$1.04B	$269.93M	$465.38M
Cash & equivalents	$1.31B	$1.56B	$282.03M	$1.66B
Total assets	$7.59B	$7.88B	$3.68B	$4.97B
Total liabilities	$1.51B	$783.80M	n/a	$4.18B
Shareholders' equity	$6.09B	$7.10B	-$70.79M	$789.18M
Return on year-end equity	5.7%	18.8%	n/a	39.8%
Shares outstanding	192.30M	43.64M	n/a	132.38M

n/a means the company did not report that line under the concept TickerFacts maps, not that it is zero.

Revenue, most recent five fiscal years

Fiscal year	BioMarin Pharmaceutical Inc	United Therapeutics Corp	Amneal Pharmaceuticals, Inc.	Alnylam Pharmaceuticals, Inc.
Latest	$3.22B Ended 2025-12-31	$3.18B Ended 2025-12-31	$3.02B Ended 2025-12-31	$3.71B Ended 2025-12-31
1 year earlier	$2.85B Ended 2024-12-31	$2.88B Ended 2024-12-31	$2.79B Ended 2024-12-31	$2.25B Ended 2024-12-31
2 years earlier	$2.42B Ended 2023-12-31	$2.33B Ended 2023-12-31	$2.39B Ended 2023-12-31	$1.83B Ended 2023-12-31
3 years earlier	$2.10B Ended 2022-12-31	$1.94B Ended 2022-12-31	$2.21B Ended 2022-12-31	$1.04B Ended 2022-12-31
4 years earlier	$1.85B Ended 2021-12-31	$1.69B Ended 2021-12-31	$2.09B Ended 2021-12-31	$844.29M Ended 2021-12-31